Clinical trials in Warsaw – page 27

1 804 clinical trials in Warsaw, Poland across 33 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Warsaw at a glance

1 804

clinical trials

Research sites33

Quick filters

1 804 trials in Warsaw

Open in trial search

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:BGB-16673
Sponsor:BeOne Medicines AG

Contact Research Centre

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Poland

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Ospedale Pediatrico Bambino Gesu

Contact Research Centre

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Recruiting

Investigational

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Ro7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Janssen Cilag International

Contact Research Centre

Non-small cell lung cancer stage IV

Recruiting

A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Janssen Cilag International

Contact Research Centre

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

Poland

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Hypertrophic cardiomyopathy+1

Recruiting

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Imbria Pharmaceuticals Inc.

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Dermatitis atopic

Recruiting

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Ro7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Warsaw

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Studies include evaluation of novel vaccine formulations and immune responses in various age groups.

RSV Prevention Studies
Influenza Vaccine Research
Respiratory Infection Management

Particular emphasis on vaccine development for adults aged 60 and older.

02 Immunology Studies

Comprehensive research on meningococcal vaccines across different age groups, from infants to toddlers. Studies evaluate safety profiles and immune responses to various vaccine formulations.

Pediatric Vaccine Development
Immunogenicity Assessment
Vaccine Safety Monitoring

Focus on preventive healthcare through advanced vaccination strategies.

03 Dermatology Research

Studies investigating treatments for psoriasis and psoriatic arthritis, including novel biological therapies and their mechanisms of action.

Plaque Psoriasis Treatment
Biomarker Analysis
Combined Therapy Approaches

Emphasis on moderate to severe cases requiring advanced therapeutic interventions.

04 Oncology Studies

Clinical research focusing on bladder cancer and innovative combination therapies. Studies evaluate treatment efficacy in early-stage non-muscle invasive cases.

Immunotherapy Research
Cancer Treatment Combinations
Disease-Free Survival Analysis

Integration of targeted therapies with standard treatments.

Back to Poland All countries